KNSA

SEC source: 0001415889-23-013044 · form4-09062023_110936.xml · nonDerivative · entry 1

Patel Sanj K · CIK 0001532218 · Director · CHAIRMAN & CEO

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 52,566

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 7

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 42,544

Underlying: Class A Common Share · 42,544 shares

Expires 2033-08-31

F4 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 6

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 7,091

Underlying: Class A Common Share · 7,091 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.

F3 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · derivative · entry 5

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,178

Underlying: Class A Common Share · 2,727 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 2

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 121,993

SEC source: 0001415889-23-013040 · form4-09062023_110948.xml · nonDerivative · entry 1

Tessari Eben · CIK 0001867899 · CHIEF OPERATING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 122,794

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 9

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 38,974

Underlying: Class A Common Share · 38,974 shares

Expires 2033-08-31

F6 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 8

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 6,496

Underlying: Class A Common Share · 6,496 shares

Expires not disclosed

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F5 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2023.

F6 · derivative.expiration_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

SEC source: 0001415889-23-013038 · form4-09062023_110943.xml · derivative · entry 7

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 7,492

Underlying: Class A Common Share · 2,498 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F4 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

F4 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, September 1, 2022.

SEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 2

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 43,674

SEC source: 0001415889-23-013038 · form4-09062023_110943.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 44,408

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-011525 · form4-07272023_080730.xml · derivative · entry 5

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 140,217

Underlying: Class A Common Share · 29,000 shares

Expires 2026-09-13

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.

F5 · derivative.exercise_date: The option is fully vested and exercisable.

SEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 4

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 41,910

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.

F4 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $19.50 to $19.94. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 3

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 49,542

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.

F3 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $18.50 to $19.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 2

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 65,710

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.

F2 · price: This transaction was executed in multiple trades through a broker-dealer at prices ranging from $17.50 to $18.49. The price reported in this column reflects the weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

SEC source: 0001415889-23-011525 · form4-07272023_080730.xml · nonDerivative · entry 1

Paolini John F. · CIK 0001741533 · CHIEF MEDICAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 70,910

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan executed by the reporting person on August 16, 2022.

SEC source: 0001415889-23-013048 · form4-09062023_110926.xml · nonDerivative · entry 1

Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 13,558

F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

SEC source: 0001415889-23-013046 · form4-09062023_110933.xml · nonDerivative · entry 1

Moat Ross · CIK 0001857177 · CHIEF COMMERCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,845

F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2023 to July 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c).

SEC source: 0001415889-23-010564 · form4-07032023_040714.xml · derivative · entry 3

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F3 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010564 · form4-07032023_040714.xml · nonDerivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-010563 · form4-07032023_040710.xml · derivative · entry 2

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010563 · form4-07032023_040710.xml · nonDerivative · entry 1

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-010562 · form4-07032023_040708.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010562 · form4-07032023_040708.xml · nonDerivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-010561 · form4-07032023_040706.xml · derivative · entry 2

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010561 · form4-07032023_040706.xml · nonDerivative · entry 1

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-010560 · form4-07032023_040703.xml · derivative · entry 2

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010560 · form4-07032023_040703.xml · nonDerivative · entry 1

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-010559 · form4-07032023_040701.xml · derivative · entry 2

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Class A Common Shares · 5,000 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

F2 · derivative.expiration_date: The RSUs vested in a single installment on June 29, 2023; there was no expiration date for the RSUs.

SEC source: 0001415889-23-010559 · form4-07032023_040701.xml · nonDerivative · entry 1

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 5,000

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001209191-23-035547 · doc4.xml · derivative · entry 6

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

BAKER JULIAN · CIK 0001087939 · Director

BAKER FELIX · CIK 0001087940 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 52,472

Underlying: Class A Common Shares · 52,472 shares

Expires 2033-06-05

F11 · shares: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

F11 · derivative.exercise_date: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified options exercisable solely into Class A Common Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Common Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Common Shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker and Dr. Biggar of 4,373 RSUs on Table I and 26,236 Share Options on Table II. These grants, totaling 8,746 RSUs and 52,472 Share Options for Felix J. Baker and Dr. Biggar in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F10 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Common Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

F11 · ownership.nature: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

SEC source: 0001209191-23-035547 · doc4.xml · derivative · entry 5

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

BAKER JULIAN · CIK 0001087939 · Director

BAKER FELIX · CIK 0001087940 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 52,472

Underlying: Class A Common Shares · 52,472 shares

Expires 2033-06-05

F11 · shares: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

F11 · derivative.exercise_date: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Common Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified options exercisable solely into Class A Common Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Common Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Common Shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker and Dr. Biggar of 4,373 RSUs on Table I and 26,236 Share Options on Table II. These grants, totaling 8,746 RSUs and 52,472 Share Options for Felix J. Baker and Dr. Biggar in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F11 · ownership.nature: Includes 26,236 Share Options granted by the Issuer to each of Felix J. Baker and Dr. Biggar on June 6, 2023, pursuant to the Incentive Award Plan. The Share Options have a strike price of $15.19, vest in 12 equal monthly installments and expire 10 years from the date of grant.

SEC source: 0001209191-23-035547 · doc4.xml · nonDerivative · entry 4

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

BAKER JULIAN · CIK 0001087939 · Director

BAKER FELIX · CIK 0001087940 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 2,719,343

F3 · shares: Includes 4,373 restricted stock units (each an "RSU") payable solely in Class A Common Shares granted by the Issuer to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP (the "Adviser") on June 6, 2023, pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker and Dr. Biggar serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F3 · ownership.nature: Includes 4,373 restricted stock units (each an "RSU") payable solely in Class A Common Shares granted by the Issuer to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP (the "Adviser") on June 6, 2023, pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker and Dr. Biggar serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified options exercisable solely into Class A Common Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Common Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Common Shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker and Dr. Biggar of 4,373 RSUs on Table I and 26,236 Share Options on Table II. These grants, totaling 8,746 RSUs and 52,472 Share Options for Felix J. Baker and Dr. Biggar in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

F10 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Brothers Life Sciences Capital, L.P. and (ii) Life Sciences, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Common Shares reported in column 5 of Table I and the Share Options reported in column 9 of Table II held directly by or held for the benefit of Life Sciences, a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital, L.P., a limited partnership of which the sole general partner is Baker Brothers Life Sciences Capital (GP), LLC, due to their interest in Life Sciences and Baker Brothers Life Sciences Capital, L.P.'s right to receive an allocation of a portion of the profits from Life Sciences.

SEC source: 0001209191-23-035547 · doc4.xml · nonDerivative · entry 3

BAKER BROS. ADVISORS LP · CIK 0001263508 · Director

667, L.P. · CIK 0001551139 · Director

BAKER JULIAN · CIK 0001087939 · Director

BAKER FELIX · CIK 0001087940 · Director

Baker Bros. Advisors (GP) LLC · CIK 0001580575 · Director

Baker Brothers Life Sciences LP · CIK 0001363364 · Director

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnotes

Disclosed balance after: 117,726

F3 · shares: Includes 4,373 restricted stock units (each an "RSU") payable solely in Class A Common Shares granted by the Issuer to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP (the "Adviser") on June 6, 2023, pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker and Dr. Biggar serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F3 · ownership.nature: Includes 4,373 restricted stock units (each an "RSU") payable solely in Class A Common Shares granted by the Issuer to each of Felix J. Baker, a managing member of Baker Bros. Advisors (GP) LLC (the "Adviser GP") and Dr. Stephen R. Biggar, an employee of Baker Bros. Advisors LP (the "Adviser") on June 6, 2023, pursuant to the Issuer's 2018 Incentive Award Plan (the "Incentive Award Plan"). The RSUs fully vest on the first anniversary of the grant date subject to the applicable director's continuous service on the board of directors of the Issuer (the "Board") through the vesting date. Felix J. Baker and Dr. Biggar serve on the Board as representatives of 667, L.P. ("667") and Baker Brothers Life Sciences, L.P. ("Life Sciences", and together with 667, the "Funds").

F4 · ownership.nature: After giving effect to the transactions reported herein and as a result of their ownership interest in (i) Baker Biotech Capital, L.P. and (ii) 667, Julian C. Baker and Felix J. Baker each may be deemed to have an indirect pecuniary interest in Class A Common Shares reported in column 5 of Table I and the Share Options (as defined below) reported in column 9 of Table II held directly by or held for the benefit of 667, a limited partnership of which the sole general partner is Baker Biotech Capital, L.P., a limited partnership of which the sole general partner is Baker Biotech Capital (GP), LLC, due to their interest in 667 and Baker Biotech Capital, L.P.'s right to receive an allocation of a portion of the profits from 667.

F5 · ownership.nature: Pursuant to the policies of the Adviser, Felix J. Baker and Dr. Biggar do not have a right to any of the Issuer's securities issued as compensation for their service on the Board and the Funds are entitled to an indirect proportionate pecuniary interest in the securities. The Funds each own an indirect proportionate pecuniary interest in the non-qualified options exercisable solely into Class A Common Shares ("Share Options") and RSUs. Solely as a result of their ownership interest in (i) the general partners of the Funds and (ii) the Funds, Felix J. Baker and Julian C. Baker may be deemed to have an indirect pecuniary interest in the Share Options, RSUs and any Class A Common Shares acquired upon the exercise of Share Options or vesting of RSUs (i.e. no direct pecuniary interest).

F6 · ownership.nature: The Adviser serves as the investment adviser to the Funds. In connection with the services provided by the Adviser, the Adviser receives an asset-based management fee that does not confer any pecuniary interest in the securities held by the Funds. The Adviser GP is the Adviser's sole general partner. Julian C. Baker and Felix J. Baker are managing members of the Adviser GP. The Adviser has complete and unlimited discretion and authority with respect to the investment and voting power of the securities held by the Funds. The general partners of the Funds relinquished to the Adviser all discretion and authority with respect to the investment and voting power of the securities held by the Funds.

F7 · ownership.nature: Julian C. Baker, Felix J. Baker, the Adviser GP and the Adviser disclaim beneficial ownership of the securities held directly by or held for the benefit of the Funds except to the extent of their pecuniary interest therein, and this report shall not be deemed an admission that any of Julian C. Baker, Felix J. Baker, the Adviser GP or the Adviser is a beneficial owner of such securities for purposes of Section 16 or any other purpose.

F8 · ownership.nature: Pursuant to agreements between Felix J. Baker, Dr. Biggar and the Adviser and the policies of the Adviser, the Adviser has voting and dispositive power over the Share Options, RSUs and any Class A Common Shares received as a result of the exercise of Share Options or vesting of RSUs.

F9 · ownership.nature: The acquisitions of the RSUs and Share Options reported on this form represent grants to each of Felix J. Baker and Dr. Biggar of 4,373 RSUs on Table I and 26,236 Share Options on Table II. These grants, totaling 8,746 RSUs and 52,472 Share Options for Felix J. Baker and Dr. Biggar in the aggregate, are reported for each of the Funds as each has an indirect pecuniary interest in such securities.

SEC source: 0001415889-23-009430 · form4-06082023_080600.xml · derivative · entry 2

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009430 · form4-06082023_080600.xml · derivative · entry 1

Malley Thomas · CIK 0001403322 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-009429 · form4-06082023_080635.xml · derivative · entry 2

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009429 · form4-06082023_080635.xml · derivative · entry 1

Popovits Kimberly J · CIK 0001333482 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-009428 · form4-06082023_080610.xml · derivative · entry 2

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009428 · form4-06082023_080610.xml · derivative · entry 1

Levy Richard S · CIK 0001454983 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-009426 · form4-06082023_080630.xml · derivative · entry 2

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009426 · form4-06082023_080630.xml · derivative · entry 1

Quart Barry D · CIK 0001384243 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-009424 · form4-06082023_080641.xml · derivative · entry 2

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009424 · form4-06082023_080641.xml · derivative · entry 1

Cole G Bradley · CIK 0001337798 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-009421 · form4-06082023_080616.xml · derivative · entry 2

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,373

Underlying: Class A Common Shares · 4,373 shares

Expires not disclosed

F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F3 · derivative.exercise_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

F3 · derivative.expiration_date: The RSUs vest in their entirety on the first anniversary of the date of the grant, June 6, 2023.

SEC source: 0001415889-23-009421 · form4-06082023_080616.xml · derivative · entry 1

McCain Tracey L · CIK 0001683600 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 26,236

Underlying: Class A Common Shares · 26,236 shares

Expires 2033-06-05

F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve substantially equal monthly installments following the date of the grant. The date of the grant is June 6, 2023.

SEC source: 0001415889-23-007004 · form4-04282023_040401.xml · derivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,981

Underlying: Class A Common Share · 990 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021.

SEC source: 0001415889-23-007004 · form4-04282023_040401.xml · nonDerivative · entry 2

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,414

SEC source: 0001415889-23-007004 · form4-04282023_040401.xml · nonDerivative · entry 1

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 12,705

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

SEC source: 0001415889-23-006441 · form4-04112023_090443.xml · derivative · entry 3

Ragosa Mark · CIK 0001835458 · CHIEF FINANCIAL OFFICER

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,082

Underlying: Class A Common Share · 2,695 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer.

F2 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.

F2 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022.